The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model

Biomaterials

Volumn 31, Issue 3, 2010, Pages 541-551

  Tan, Mei L ^a,b   Friedhuber, Anna M ^b   Dunstan, Dave E ^b   Choong, Peter F M ^a,b,c   Dass, Crispin R ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cancer; Chitosan; Doxorubicin; Drug delivery; Microparticle; Osteosarcoma

Indexed keywords

APOPTOSIS; AUTOPHAGIC CELLS; BONE CANCER; CANCER; CHILDREN AND ADOLESCENTS; COMPLEX COACERVATION; DISEASE FREE SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEM; DRY SKIN; FRONTLINE; HEART FAILURE; HIGH DOSE; MANAGEMENT STRATEGIES; MICRO-PARTICLES; MICROPARTICLE; MYELOSUPPRESSION; OPTIMISATIONS; ORTHOTOPIC; OSTEOSARCOMA; SIDE EFFECT; SULPHATES; TUMOR GROWTH; TUMOR INHIBITION; TUMOR SITE; TUMOR VOLUMES;

BONE; CELL DEATH; CHEMOTHERAPY; CHITIN; CHITOSAN; DEXTRAN; DRUG DELIVERY; GLUCOSE; PATHOLOGY; TUMORS;

DRUG DOSAGE;

CHITOSAN; DEXTRAN SULFATE; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; BODY WEIGHT; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; ENCAPSULATION; EXPERIMENTAL DESIGN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TUMOR VOLUME;

ADOLESCENT; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOCOMPATIBLE MATERIALS; CELL LINE; CHILD; CHITOSAN; DEXTRAN SULFATE; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MATERIALS TESTING; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA;

MUS;

EID: 70449115553     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.09.069     Document Type: Article

References (35)

1. Tan M.L., Choong P.F., and Dass C.R. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 61 1 (2009) 3-12
2. Tan M.L., Choong P.F., and Dass C.R. Doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 61 2 (2009) 131-142
3. Roy K., Mao H.Q., Huang S.K., and Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5 4 (1999) 387-391
4. Dass C.R., Friedhuber A.M., Khachigian L.M., Dunstan D.E., and Choong P.F. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J Microencapsul (2008) 1-5
5. Janes K.A., Fresneau M.P., Marazuela A., Fabra A., and Alonso M.J. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 73 2-3 (2001) 255-267
6. Lee E., Lee J., Lee I.H., Yu M., Kim H., Chae S.Y., et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 51 20 (2008) 6442-6449
7. Wood J. Doxorubicin. In: Allwood M., Stanley A., and Wright P. (Eds). The cytotoxics handbook. 4th ed. (2002), Radcliffe Medical Press Ltd, Oxon, U.K. 322-329
8. Rubin E.H., and Hait W.N. Chemotherapeutic agents: micro-tubule targeting agents. In: Kufe D.W., Pollock R.E., Weichselbaum R.R., Bast R.C.J., Gansler T.S., Holland J.F., et al. (Eds). Cancer medicine. 6th ed (2003), BC Decker Inc, Hamilton, Canada
9. Kremer L.C., van Dalen E.C., Offringa M., and Voute P.A. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 13 4 (2002) 503-512
10. Longhi A., Ferrari S., Bacci G., and Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 18 6 (2007) 737-744
11. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33 3 Suppl. 8 (2006) S2-S7
12. Pein F., Sakiroglu O., Dahan M., Lebidois J., Merlet P., Shamsaldin A., et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 91 1 (2004) 37-44
13. Ortho-Biotech. DOXIL (R) - Doxorubicin HCL liposome injection ortho-biotech, U.S. [updated Feb 19 2009]. Available from:. http://www.orthobiotech.com/orthobiotech/doxil.html
14. Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., and Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 18 7 (2007) 1159-1164
15. Dorfman H.D., and Czerniak B. Bone cancers. Cancer 75 1 Suppl. (1995) 203-210
16. Longhi A., Errani C., De Paolis M., Mercuri M., and Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32 6 (2006) 423-436
17. Weeden S., Grimer R.J., Cannon S.R., Taminiau A.H., Uscinska B.M., and European osteosarcoma intergroup. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 37 1 (2001) 39-46
18. Kumar V., Cotran R.S., and Robbins S.L. Neoplasia. robbins basic pathology. 7th ed. (2003), Ed. Saunders, Philadelphia, Pennsylvania, U.S. p. 165-210
19. Mao H.Q., Roy K., Troung-Le V.L., Janes K.A., Lin K.Y., Wang Y., et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 70 3 (2001) 399-421
20. Dass C.R., Ek E.T., Contreras K.G., and Choong P.F. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis 23 7-8 (2006) 367-380
21. Berlin O., Samid D., Donthineni-Rao R., Akeson W., Amiel D., and Woods Jr. V.L. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 53 20 (1993 Oct 15) 4890-4895
22. Tinari A., Giammarioli A.M., Manganelli V., Ciarlo L., and Malorni W. Analyzing morphological and ultrastructural features in cell death. Meth Enzymol 442 (2008) 1-26
23. Galluzzi L., Maiuri M.C., Vitale I., Zischka H., Castedo M., Zitvogel L., et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14 7 (2007) 1237-1243
24. Takemura G., and Fujiwara H. Morphological aspects of apoptosis in heart diseases. J Cell Mol Med 10 1 (2006) 56-75
25. Kroemer G., El-Deiry W.S., Golstein P., Peter M.E., Vaux D., Vandenabeele P., et al. Classification of cell death: recommendations of the nomenclature committee on cell death. Cell Death Differ 12 Suppl. 2 (2005) 1463-1467
26. Malorni W., Matarrese P., Tinari A., Farrace M.G., and Piacentini M. Xeno-cannibalism: a survival "escamotage". Autophagy 3 1 (2007) 75-77
27. Ng B., Wolf R.F., Weksler B., Brennan M.F., and Burt M. Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin. Cancer Res 53 22 (1993) 5483-5486
28. Young D.M., Fioravanti J.L., Olson H.M., and Prieur D.J. Chemical and morphologic alterations of rabbit bone induced by adriamycin. Calcif Tissue Res 18 1 (1975 Jul 4) 47-63
29. Pereverzeva E., Treschalin I., Bodyagin D., Maksimenko O., Kreuter J., and Gelperina S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol Lett 178 1 (2008) 9-19
30. Liu T.J., Yeh Y.C., Ting C.T., Lee W.L., Wang L.C., Lee H.W., et al. Ginkgo biloba extract 761 reduces doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes. Cardiovasc Res 80 2 (2008) 227-235
31. Di Costanzo F., Gasperoni S., Manzione L., Bisagni G., Labianca R., Bravi S., et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100 6 (2008) 388-398
32. Masci E., Mangiavillano B., Albarello L., Mariani A., Doglioni C., and Testoni P.A. Pilot study on the correlation of optical coherence tomography with histology in celiac disease and normal subjects. J Gastroenterol Hepatol 22 12 (2007) 2256-2260
33. Howarth G.S., Tooley K.L., Davidson G.P., and Butler R.N. A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat. Cancer Biol Ther 5 9 (2006) 1189-1195
34. Amoh Y., Li L., Katsuoka K., and Hoffman R.M. Chemotherapy targets the hair-follicle vascular network but not the stem cells. J Invest Dermatol 127 1 (2007) 11-15
35. Selleri S., Seltmann H., Gariboldi S., Shirai Y.F., Balsari A., Zouboulis C.C., et al. Doxorubicin-induced alopecia is associated with sebaceous gland degeneration. J Invest Dermatol 126 4 (2006) 711-720